Search

Cardiac lipomas are rarely diagnosed tumors of heart. They are encapsulated and matured lipoid tumors that are diagnosed equally in all age groups and sexes. Cardiac lipoma are diagnosed mostly in the left ventricle, right atrium, and interatrial septum. We present a 62-year-old symptomatic patient with right atrial lipoma suffering from effort dyspnea, upper extremity and facial edema and palpitation, and who had a by-pass operation approximately 1.5 years ago. In patient transthorasic echocardiography (TTE) revealed that the right atrial mass. It was decided that the audience may be receiving. She underwent interatrial septum resection followed by reconstruction of interatrial septum and atriocaval junction. In the third month after the operation, there was no intracardiac mass on TTE and right atrial size was within normal limits.

Measurement of circulating cardiac biomarkers has enabled early diagnosis and risk assessment of acute coronary syndrome. Heart type fatty acid binding protein (H-FABP) is a relatively novel marker for the diagnosis of myocardial injury. The purpose of the present study was to compare H-FABP with Troponin I (cTnI) and creatine kinase myocardial band (CK-MB) in determining myocardial injury in patients with early stage of percutaneous coronary intervention (PCI). Blood was withdrawn one hour before and 3 hours after PCI from 40 patients to measure H-FABP, cTnI and CKMB. H-FABP was measured qualitatively. CK-MB and cTnI were measured by a sandwich enzyme-linked immunosorbent assay. Before PCI, H-FABP was found to be negative, while cTnI and CK-MB were found to be in normal ranges. Statistical analysis of measurements 3 hours after PCI revealed that H-FABP was significantly positive in 15 (37%) patients, while cTnI was elevated in 11 (27%) patients and CKMB was elevated in 8 (20%) patients. H-FABP is statistically more sensitive than cTnI and CK-MB at detecting myocardial injury after PCI.H-FABP can be used in early stages to detect myocardial injury caused by PCI. H-FABP is more sensitive than cTnI and CK-MB in determining myocardial injury due to PCI within 3 hours. H-FABP may help us stratify a patient's risk in early stages after PCI.

Coexisting coronary artery disease (CAD) is an important cause of morbidity and mortality in patients with peripheral arterial disease (PAD). Clinical evaluation and noninvasive tests have some important limitations for the detection of CAD in patients with PAD. The purpose of this study was to investigate whether urinary albumin excretion (UAE) was a sign of atherosclerotic involvement of coronary arteries in patients with PAD. Our study consisted of 65 consecutive patients (56 men, 9 women, mean age; 59.7 ±7.9 years) with PAD who underwent coronary angiography. Urinary albumin excretion was measured in 24-hour urine samples by immunoprecipitation technique. PAD was defined as the presence of ≥50% stenotic lesions in at least 1 of the iliac, femoral, popliteal, tibialis anterior, tibialis posterior, or peroneal arteries. CAD was defined as ≥25% diameter stenosis in at least 1 coronary artery. Patients without any coronary lesions were accepted as having normal coronaries. Age, sex, distributions of coronary risk factors, and UAE rates were compared between patients with and without CAD. Mean UAE was 17.9 ±15.6 mg/day in the total population. Thirty-seven percent of patients had CAD, and 63% had no coronary lesion. UAE rates were 22.33 ±18.74 and 15.32 ±13.01 mg/day in patients with CAD and those with normal coronary arteries, respectively (p=0.021). Microalbuminuria was detected in 25% in patients with CAD and 12% in those without coronary artery lesions (p=0.184). The difference was not statistically significant. The distributions of other risk factors and sex were not different between the 2 groups. These data suggest that in patients with PAD, urinary albumin excretion rates may be used to determine those with a high probability of CAD. Further studies are required to decide whether this noninvasive testing is appropriate in detecting high-risk patients.

pectoris, myocardial infarction (MI) or sudden death.1 What caused dissection in our patient who was not at a usual age for idiopathic SCAD? In polycythemia vera (PV), thrombosis due to hyperviscosity and thrombocytosis is mostly concerned as the origin of the coronary ischemic complications. In one study, some histological alterations were shown in coronary intima.2 We hereby report a case of SCAD on the grounds of PV and discuss the association SCAD and PV.

The aims of our study were to assess the distribution of interventional and other therapeutic procedures performed on subjects who had proven CAD by angiography in our clinic; to determine the groups of therapeutic agents prescribed at the time of discharge; and to compare these with the results of EUROASPIRE II, which examined the prophylactic drug therapy upon discharge of CAD patients in 15 European countries.Our patients comprises of 617 subjects (516 male, 101 female; mean age 57.2 +/- 10.8 years) who underwent coronary angiography for the first time in our clinic and who were found to have a 50% lesion in at least one of the coronary arteries. In all patients distribution of risk factors on admission, distribution of therapeutic procedures and the use of drug therapies at the hospital discharge were recorded.We found that, 68% of our cases were considered to be eligible for a percutaneous or surgical intervention, while 27% were assessed not as requiring such an intervention and consequently were discharged being prescribed appropriate medications. For the remaining 5% of the subjects, tests for detection of viable myocardium were advised, before selecting the proper type of management. At discharge, prescription rates for antiplatelets, beta-blockers, nitrates, statins, angiotensin-converting enzyme inhibitors (ACE-I), calcium channel blockers and anticoagulants were detected to be %99, 86%, 86%, 63%, 40%, 16%, and 2% respectively.Compared with the results of EUROASPIRE II study, these data show that, antiplatelet, beta-blocker, ACE-I and lipid-lowering treatments our subjects received upon discharge were higher, whereas anticoagulant treatment was lower than the averages of the fifteen European countries consisting the EUROASPIRE II study.

Background: Coronary artery disease (CAD) is the leading cause of adult deaths in our country. In clinical practice, an adequate level of secondary prevention towards CAD primarily requires full recognition of the distribution of risk factors. The aim of our study was to determine the prevalence of coronary risk factors and the use of prophylactic drugs among patients who have an angiographically proven CAD in our centre, and to compare it with those of the EUROASPIRE I and II studies. Design: Cross-sectional, observational study. Methods: Our patients comprise 617 subjects (516 male, mean age 57.2 +/- 10.8 years) who underwent an angiography between January 2000 and May 2000 for the first time and in whom significant coronary lesions were detected. Age, gender, family history of premature CAD (FH), diabetes mellitus (DM), hypertension (HT), lipid profile, smoking, body mass index, waist circumference, hip circumference and physical activity data were recorded prior to angiography. The medical treatments received by these cases at discharge from hospital were investigated. Data thus obtained were compared with the results of the EUROASPIRE I and II trials, which studied the frequency of existing risk factors and prophylactic drug use among CAD patients in European countries. Results: Hyperlipidaemia, FH, DM, HT, smoking, obesity, central obesity were found in 52, 26, 20, 41, 65, 18 and 29% of patients, respectively. The use of antiplatelets, beta-blockers, ACE inhibitors, statins and calcium antagonists were 99, 86, 40, 63 and 16%, respectively. Conclusion: Upon comparison of the risk factors, prevalence of obesity and DM was found to be similar to the average of nine European countries among our subjects. Smoking was found to be considerably higher, whereas HT, hyperlipidaemia and family history of premature CAD were lower than the European average within our subjects. In our cases the frequency of prophylactic drug usage at discharge was higher than the European means.